Poxviral promoters for improving the immunogenicity of MVA delivered vaccines
Modified vaccinia virus Ankara (MVA) is a replication-deficient poxvirus, attenuated in chick embryo fibroblast primary cells. It has been utilised as a viral vector to develop many vaccines against cancer and infectious diseases such as malaria, HIV/AIDS, influenza, and tuberculosis, MERS-CoV, and...
Saved in:
Main Author: | Naif Khalaf Alharbi (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2019-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models
by: Lynette Siv Chea, et al.
Published: (2017) -
The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial.
by: Anne Wajja, et al.
Published: (2017) -
Vaccines against mpox: MVA-BN and LC16m8
by: John D. Grabenstein, et al.
Published: (2024) -
Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model
by: Christelle Remy-Ziller, et al.
Published: (2018) -
A novel MVA vectored Chikungunya virus vaccine elicits protective immunity in mice.
by: James Weger-Lucarelli, et al.
Published: (2014)